Benchsci Raises $63 Million Series C To Solve Pharma's Biggest R&D Challenges With Ai-Powered Software Platform
PRIVATEJan 24, 2022
Amount Raised
$63 Million
Round Type
Series C
TorontoInformation TechnologySoftware
Description
BenchSci, a global leader in machine learning applications for novel medicine development, today announced a $63 million Series C (US $50 Million) funding round led by Inovia Capital and TCV, with participation from existing investors.
Who to call at BenchSci, and when
A new round usually means BenchSci is about to hire and buy. The teams that reach out first get the meeting.
An alert the day BenchSci raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at BenchSci, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BenchSci. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
BenchSci
Location
Toronto, Ontario, Canada
About
BenchSci’s vision is to exponentially increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.
Backed by F-Prime, Gradient Ventures (Google’s AI fund), Inovia Capital, and TCV, our platform accelerates science at 16 of the top-20 pharmaceutical companies, and over 4,300 leading research centers worldwide.
We’re a remote-first company recognized for our impact and culture as a Deloitte Tech Fast 50TM, CIX Top 10 Growth, Great Place to Work®, and top-ranked organization on Glassdoor.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BenchSci raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TorontoInformation TechnologySoftware